Top Neurological Biomarkers Market Leading Companies And Growth Forecast, Global industry Outlook to 2034

 

Meta Title:
Neurological Biomarkers Market Trends, Key Players & Industry Forecast

Meta Description:
Analyze key trends shaping the Neurological Biomarkers Market, featuring leading companies, innovation strategies, regulatory developments, and future growth projections.

Meta Keywords:
neurological biomarkers market, global neurological biomarkers market, brain biomarkers market, neurological diagnostics market, biomarker technology market, neuroscience biomarkers, biomarker industry analysis, neurological disease detection market.

Market Size and Overview  

The global Neurological Biomarkers Market was valued at approximately USD 9.5 billion in 2026 and is projected to reach USD 19.1 billion by 2034, growing at a CAGR of 12.9% during the forecast period. The market is driven by the increasing prevalence of neurological disorders, rising demand for early and accurate diagnosis, and growing adoption of precision medicine.

Neurological biomarkers are biological indicators used to detect, diagnose, monitor, and predict the progression of disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, and other neurodegenerative conditions. Advancements in biomarker discovery technologies, including genomics, proteomics, neuroimaging, and blood-based testing, are enhancing diagnostic capabilities and supporting the development of targeted therapies.

Key Insights

• Growing incidence of neurodegenerative and neurological diseases is fueling market demand.
• Early disease detection and personalized treatment approaches are increasing biomarker adoption.
• Pharmaceutical and biotechnology companies are major end users, leveraging biomarkers in drug discovery and clinical trials.
• Alzheimer's disease biomarkers represent a leading application segment due to the rising global dementia burden.
• North America dominates the market, while Asia-Pacific is expected to witness the fastest growth due to improving healthcare infrastructure and increasing research investments.

 

Access the full Report on Neurological Biomarkers Market

 

Key Market Drivers:

• Rising prevalence of Alzheimer's, Parkinson's, and other neurological disorders.
• Growing demand for early and accurate disease diagnosis.
• Advancements in genomics, proteomics, and neuroimaging technologies.
• Increasing adoption of precision medicine and personalized treatments.
• Higher investments in neurological research and drug development.

Market Demand:
Demand for neurological biomarkers is growing due to their crucial role in early detection, disease monitoring, and drug discovery. Pharmaceutical companies, diagnostic laboratories, and research institutions are increasingly adopting biomarker-based solutions to improve patient outcomes and accelerate therapeutic development.

Market Segmentation

By Biomarker Type (Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers, Other Biomarkers)

By Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Stroke, Autism Spectrum Disorder, Other Neurological Disorders)

By End User (Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Hospitals & Clinics, Research Institutes & Academic Centers)

By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa)

 

Top Companies in the Neurological Biomarkers Market

• Quanterix Corporation
• Fujirebio Holdings, Inc.
• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• QIAGEN N.V.
• Merck KGaA
• Banyan Biomarkers, Inc.
• C2N Diagnostics, LLC

1. Quanterix Corporation

Quanterix Corporation is one of the most recognized innovators in the neurological biomarkers market, specializing in ultra-sensitive biomarker detection technologies. The company’s proprietary Simoa (Single Molecule Array) platform enables the measurement of neurological biomarkers at extremely low concentrations in blood, serum, plasma, and cerebrospinal fluid, supporting early detection and monitoring of neurological disorders. Its portfolio includes assays for Neurofilament Light (NfL), Tau, GFAP, Amyloid Beta, and other biomarkers used in Alzheimer's disease, multiple sclerosis, traumatic brain injury, and neurodegenerative research.

The company has established a strong global presence through collaborations with pharmaceutical companies, research institutions, and clinical laboratories. Quanterix continues to expand its neurology-focused diagnostic capabilities through assay development, biomarker validation programs, and strategic partnerships aimed at accelerating blood-based neurological testing worldwide. Its technology has become a key tool in neurological drug development and precision medicine initiatives.

Key Highlights

• Pioneer of Simoa ultra-sensitive biomarker technology
• Strong focus on blood-based neurological diagnostics
• Extensive portfolio of NfL, Tau, GFAP, and Amyloid assays
• Collaborates with pharmaceutical and biotech companies
• Supports neurological clinical trials globally

Category	Details
Founded	2007
Headquarters	Billerica, Massachusetts, USA
Employees	Approx. 500+
Revenue	Approx. USD 130+ Million
Industry	Neurological Biomarkers & Precision Diagnostics
Key Products	Simoa Platform, NfL Assays, Tau Assays, GFAP Assays, Amyloid Beta Assays

2. Fujirebio Holdings, Inc.

Fujirebio is a leading developer of neurological biomarker diagnostics with more than three decades of expertise in neurodegenerative disease testing. The company has pioneered numerous biomarker assays for Alzheimer's disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and related neurological conditions. Its Lumipulse platform supports automated testing of blood and cerebrospinal fluid biomarkers, improving diagnostic accuracy and clinical decision-making.

Fujirebio’s strategy focuses on advancing neurological diagnostics from biomarker discovery through commercialization. The company actively develops plasma and CSF biomarker assays and collaborates with pharmaceutical and research organizations worldwide. Through acquisitions, CDMO services, and regulatory advancements, Fujirebio continues to strengthen its leadership position in neurological biomarker innovation.

Key Highlights

• Pioneer in neurodegenerative disease diagnostics
• Developer of Lumipulse neurological biomarker platform
• Strong expertise in Alzheimer's disease biomarkers
• Global biomarker development and CDMO capabilities
• Active neurological biomarker research pipeline

Category	Details
Founded	1950
Headquarters	Tokyo, Japan
Employees	Approx. 1,400+
Revenue	Approx. USD 800+ Million
Industry	In Vitro Diagnostics & Neurological Biomarkers
Key Products	Lumipulse Neurological Assays, pTau Tests, NfL Assays, Amyloid Biomarker Tests

3. Roche Diagnostics

Roche Diagnostics is a major participant in the neurological biomarkers market through its advanced biomarker testing solutions for neurodegenerative diseases. The company develops cerebrospinal fluid and blood-based biomarker assays used in Alzheimer's disease diagnosis, disease progression monitoring, and therapeutic development. Its Elecsys platform supports automated biomarker testing for amyloid and tau-related biomarkers.

Roche continues to invest heavily in neurological biomarker innovation, regulatory approvals, and clinical validation studies. Through collaborations with academic institutions and industry consortia, the company contributes significantly to biomarker standardization and broader adoption of neurological diagnostics worldwide.

Key Highlights

• Strong neurological diagnostic portfolio
• Elecsys biomarker testing platform
• Focus on Alzheimer's disease diagnostics
• Extensive clinical validation programs
• Global laboratory and diagnostic network

Category	Details
Founded	1896
Headquarters	Basel, Switzerland
Employees	Approx. 100,000+
Revenue	Approx. USD 70+ Billion
Industry	Diagnostics & Neurological Biomarkers
Key Products	Elecsys NfL Assays, Amyloid Biomarker Tests, Tau Biomarker Assays

4. Abbott Laboratories

Abbott Laboratories is a significant contributor to neurological biomarker research and diagnostic testing through its immunoassay technologies and laboratory diagnostic systems. The company develops biomarker-based testing solutions that support the identification and monitoring of neurological disorders, including neurodegenerative diseases and brain injuries.

Abbott leverages its global diagnostic infrastructure and research partnerships to enhance biomarker accessibility and clinical utility. The company continues expanding biomarker applications through advanced assay development and integration with automated diagnostic platforms.

Key Highlights

• Major diagnostics industry participant
• Advanced immunoassay technologies
• Neurological biomarker assay development
• Global laboratory diagnostic footprint
• Strong clinical research collaborations

Category	Details
Founded	1888
Headquarters	Illinois, USA
Employees	Approx. 115,000+
Revenue	Approx. USD 40+ Billion
Industry	Diagnostic Technologies & Biomarkers
Key Products	Neurological Immunoassays, Biomarker Testing Solutions, Diagnostic Platforms

5. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific supports the neurological biomarkers market through biomarker discovery technologies, proteomics platforms, genomic analysis tools, and laboratory solutions used in neurological research. Its technologies help identify, validate, and commercialize biomarkers associated with neurodegenerative diseases and neurological disorders.

The company serves pharmaceutical firms, academic institutions, and clinical researchers globally. Through continuous investment in life science technologies, Thermo Fisher enables advanced neurological biomarker research and supports precision medicine initiatives across neuroscience applications.

Key Highlights

• Comprehensive biomarker research technologies
• Strong proteomics and genomics capabilities
• Supports neurological biomarker discovery
• Global life sciences infrastructure
• Extensive pharmaceutical partnerships

Category	Details
Founded	2006
Headquarters	Massachusetts, USA
Employees	Approx. 125,000+
Revenue	Approx. USD 42+ Billion
Industry	Life Sciences & Biomarker Research
Key Products	Proteomics Platforms, Biomarker Discovery Solutions, Neurological Research Tools

6. Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories plays an important role in neurological biomarker development through digital PCR systems, multiplex immunoassays, protein analysis technologies, and research reagents. These solutions are widely used for neurological biomarker identification, validation, and translational research.

The company supports neuroscience researchers and diagnostic developers worldwide by providing highly sensitive analytical technologies. Its innovations contribute to improved biomarker discovery and validation workflows for neurological diseases.

Key Highlights

• Digital PCR expertise
• Multiplex biomarker analysis capabilities
• Supports neuroscience research
• Strong biomarker validation technologies
• Global scientific research presence

Category	Details
Founded	1952
Headquarters	California, USA
Employees	Approx. 8,000+
Revenue	Approx. USD 2.7+ Billion
Industry	Biomarker Research Technologies
Key Products	Digital PCR Systems, Multiplex Assays, Neurological Research Reagents

7. QIAGEN N.V.

QIAGEN provides molecular testing and biomarker discovery technologies that support neurological biomarker development. The company's genomic and molecular diagnostic platforms enable researchers to identify neurological disease signatures and develop precision diagnostic solutions.

QIAGEN's global network and strong focus on molecular diagnostics position it as an important contributor to biomarker-based neurology research. The company continues expanding its portfolio through innovation in sample preparation, sequencing, and bioinformatics solutions.

Key Highlights

• Molecular diagnostic expertise
• Biomarker discovery technologies
• Genomics-driven neurological research
• Global life science presence
• Advanced bioinformatics solutions

Category	Details
Founded	1984
Headquarters	Venlo, Netherlands
Employees	Approx. 6,000+
Revenue	Approx. USD 2.0+ Billion
Industry	Molecular Diagnostics & Biomarkers
Key Products	Biomarker Discovery Platforms, Molecular Testing Solutions, Genomic Analysis Tools

8. Merck KGaA

Merck KGaA contributes to the neurological biomarkers market through research tools, biomarker discovery platforms, analytical reagents, and neuroscience-focused life science solutions. The company supports biomarker identification and validation activities used in neurological disease research and drug development.

Its life science division works closely with academic researchers, biotechnology companies, and pharmaceutical organizations to accelerate biomarker-based neurological innovations. The company continues investing in advanced analytical technologies that support precision neurology.

Key Highlights

• Biomarker research support technologies
• Strong neuroscience research portfolio
• Global life science operations
• Advanced analytical capabilities
• Supports neurological drug development

Category	Details
Founded	1668
Headquarters	Darmstadt, Germany
Employees	Approx. 63,000+
Revenue	Approx. USD 24+ Billion
Industry	Life Science & Biomarker Research
Key Products	Biomarker Discovery Reagents, Neuroscience Research Solutions, Analytical Platforms

9. Banyan Biomarkers, Inc.

Banyan Biomarkers specializes exclusively in biomarker technologies for neurological injuries and diseases. The company is known for developing blood-based biomarkers that assist in the diagnosis and management of traumatic brain injury (TBI) and other neurological conditions.

Its strategic focus on neurological diagnostics has enabled the company to become a recognized innovator in brain injury biomarker development. Banyan continues expanding clinical applications for blood-based neurological testing through research partnerships and regulatory initiatives.

Key Highlights

• Specialized neurological biomarker company
• Focus on traumatic brain injury diagnostics
• Blood-based neurological testing expertise
• Strong biomarker innovation pipeline
• Clinical diagnostic development focus

Category	Details
Founded	2002
Headquarters	Florida, USA
Employees	Approx. 100+
Revenue	Private Company
Industry	Neurological Biomarker Diagnostics
Key Products	Brain Injury Biomarker Tests, Blood-Based Neurological Assays

10. C2N Diagnostics, LLC

C2N Diagnostics is a precision diagnostics company focused on blood-based biomarker testing for neurodegenerative diseases, particularly Alzheimer's disease. The company develops advanced biomarker assays that enable earlier detection, disease stratification, and monitoring of neurological conditions.

The company has gained significant recognition for translating neurological biomarker research into clinically useful diagnostic solutions. Through collaborations with healthcare providers, pharmaceutical companies, and research organizations, C2N continues expanding access to precision neurology diagnostics worldwide.

Key Highlights

• Focused on neurodegenerative disease biomarkers
• Advanced blood-based diagnostic testing
• Strong Alzheimer's disease biomarker expertise
• Precision neurology approach
• Extensive research collaborations

Category	Details
Founded	2007
Headquarters	Missouri, USA
Employees	Approx. 200+
Revenue	Private Company
Industry	Neurological Biomarker Diagnostics
Key Products	Alzheimer's Blood Biomarker Tests, Neurodegenerative Disease Diagnostic Assays